Blue Health Intelligence® Database Powers Comparative Review of Costs of Treating a Serious Vascular Disease

BHI News

CHICAGO (July 2, 2018) – A new comparative analysis of the cost efficacy of treatment options for a serious vascular disease, based on five years of administrative claims data from the Blue Health Intelligence (BHI®) database, has been published in the Journal of Vascular Surgery. The study found significant economic benefits from the use of Flexitouch® (Tactile Medical™, Minneapolis), an advanced pneumatic compression device, compared with other devices and conservative therapy for lower-extremity swelling from chronic venous insufficiency (CVI).

As much as 11 percent of the population has CVI. Until this new study, there had been a lack of evidence comparing therapeutic interventions. The study used deidentified private insurance claims from BHI from 2012 to 2016. A total of 26,902 patients with lower-extremity swelling were identified as continuously enrolled with medical benefits for at least 12 months before and six months after the index date. Of those, 18,272 patients without a diagnosis for CVI were excluded, leaving 8,630 patients with phlebolymphedema (CVI and lower extremity swelling). Researchers could analyze health plan members’ monthly and annual costs of treatment.

BHI’s data, analytics, and consulting support data-driven initiatives for medical device companies, health plans, and third-party vendors. These include market assessments, comparative effectiveness studies, trending analyses, predictive analytic models, and research- driven medical communications.

“The scale, breadth, timeliness, and uniformity of our claims database enables researchers to quickly access a sufficient patient cohort for statistically significant findings for common and rare conditions,” said Swati Abbott, BHI’s CEO. “We are always excited to see our data used to validate the cost-effectiveness of new medical technologies that can ease the burden of chronic disease.”

About Blue Health Intelligence®

Leveraging the power of medical and pharmacy claims data from more than 180 million Americans, Blue Health Intelligence (BHI) delivers insights that empower healthcare organizations to improve patient care, reduce costs, and optimize performance. With the largest, most up-to-date, and uniform data set in healthcare, BHI provides an accurate representation of the health profile of commercially insured Americans. Our team of data analysts, clinicians, IT experts, and epidemiologists provide analytics, software as a service, and in-depth consulting to payors, providers, employers, medical device companies, and other healthcare stakeholders. Blue Health Intelligence is an independent licensee of the Blue Cross Blue Shield Association and carries the trade name of Health Intelligence Company, LLC. For more information, visit www.bluehealthintelligence.com.